Spyre Therapeutics, Inc. (SYRE) — Financial statements
Income statement, balance sheet, and cash flow for Spyre Therapeutics, Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 0.00 | 0.00↓100.0% | 0.89↓62.0% | 2↓87.6% | 19 | |
| Cost of Revenue | 172 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Gross Profit | -172 | 0.00↓100.0% | 0.89↓62.0% | 2↓87.6% | 19 | |
| Operating Expenses | ||||||
| R&D Expenses | 172↑5.4% | 163↑81.9% | 90↑52.8% | 59↑2.6% | 57 | |
| General & Administrative Expenses | 48↑4.7% | 46↑14.6% | 40↑40.0% | 29↑4.4% | 27 | |
| Selling & Marketing Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| SG&A Expenses | 48↑4.7% | 46↑14.6% | 40↑40.0% | 29↑4.4% | 27 | |
| Other Expenses | -182 | 0.00↓100.0% | 114 | 0.00 | 0.00 | |
| Operating Expenses | 38↓81.8% | 209↓14.2% | 243↑179.2% | 87↑3.2% | 84 | |
| Total Costs & Expenses | 210↑0.5% | 209↓14.2% | 243↑179.2% | 87↑3.2% | 84 | |
| Operating Results | ||||||
| Operating Income | -210↓0.5% | -209↑13.9% | -242↓185.8% | -85↓29.1% | -66 | |
| Depreciation & Amortization | 10 | 0.00↓100.0% | 0.96↓50.9% | 2↑24.6% | 2 | |
| EBITDA | -210↓0.8% | -208↓63.0% | -128↓54.1% | -83↓29.3% | -64 | |
| EBIT | -220↓5.6% | -208↓61.8% | -129↓51.6% | -85↓29.1% | -66 | |
| Interest & Other Income | ||||||
| Net Interest Income | 25↑16.8% | 21↑246.7% | 6↑634.4% | 0.84↑654.1% | 0.11 | |
| Interest Income | 25↑16.8% | 21↑246.7% | 6↑634.4% | 0.84↑654.1% | 0.11 | |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Non-Operating Income | 10↑1769.4% | -0.60↑99.5% | -114 | 0.00 | 0.00 | |
| Other Income / Expenses | 54↑8972.5% | 0.60↑100.6% | -97↓11728.1% | 0.83↑7645.5% | -0.01 | |
| Income Before Tax | -155↑25.4% | -208↑38.6% | -339↓303.6% | -84↓27.9% | -66 | |
| Income Tax Expense | -0.02↓129.4% | 0.05↑296.2% | -0.03↑80.9% | -0.14↓196.5% | 0.14 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -155↑25.4% | -208↑38.6% | -339↓304.2% | -84↓27.4% | -66 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | -155↑25.4% | -208↑38.6% | -339↓304.2% | -84↓27.4% | -66 | |
| Bottom-Line Net Income | -127↑15.4% | -150↓57.6% | -95↓13.2% | -84↓27.4% | -66 | |
| EPS (Basic) | -1.98↑37.7% | -3.18↑93.1% | -46.15↓85.6% | -24.86↑0.6% | -25.02 | |
| EPS (Diluted) | -1.98↑37.7% | -3.18↑93.1% | -46.15↓85.6% | -24.86↑0.6% | -25.02 | |
| Weighted Average Shares | 346↑635.8% | 47↑581.9% | 7↑104.6% | 3↑28.2% | 3 | |
| Weighted Average Diluted Shares | 346↑635.8% | 47↑581.9% | 7↑104.6% | 3↑28.2% | 3 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.